1. Home
  2. IOVA vs BHRB Comparison

IOVA vs BHRB Comparison

Compare IOVA & BHRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • BHRB
  • Stock Information
  • Founded
  • IOVA 2007
  • BHRB 1852
  • Country
  • IOVA United States
  • BHRB United States
  • Employees
  • IOVA N/A
  • BHRB N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • BHRB Major Banks
  • Sector
  • IOVA Health Care
  • BHRB Finance
  • Exchange
  • IOVA Nasdaq
  • BHRB Nasdaq
  • Market Cap
  • IOVA 975.1M
  • BHRB 852.6M
  • IPO Year
  • IOVA N/A
  • BHRB N/A
  • Fundamental
  • Price
  • IOVA $2.69
  • BHRB $63.69
  • Analyst Decision
  • IOVA Buy
  • BHRB Strong Buy
  • Analyst Count
  • IOVA 11
  • BHRB 3
  • Target Price
  • IOVA $11.90
  • BHRB $71.67
  • AVG Volume (30 Days)
  • IOVA 16.7M
  • BHRB 54.3K
  • Earning Date
  • IOVA 08-07-2025
  • BHRB 07-24-2025
  • Dividend Yield
  • IOVA N/A
  • BHRB 3.49%
  • EPS Growth
  • IOVA N/A
  • BHRB N/A
  • EPS
  • IOVA N/A
  • BHRB 6.89
  • Revenue
  • IOVA $241,525,000.00
  • BHRB $330,001,000.00
  • Revenue This Year
  • IOVA $86.62
  • BHRB $51.44
  • Revenue Next Year
  • IOVA $69.13
  • BHRB $3.58
  • P/E Ratio
  • IOVA N/A
  • BHRB $9.15
  • Revenue Growth
  • IOVA 636.99
  • BHRB 164.69
  • 52 Week Low
  • IOVA $1.64
  • BHRB $47.57
  • 52 Week High
  • IOVA $12.51
  • BHRB $75.32
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 54.92
  • BHRB 65.11
  • Support Level
  • IOVA $2.44
  • BHRB $57.67
  • Resistance Level
  • IOVA $2.85
  • BHRB $60.94
  • Average True Range (ATR)
  • IOVA 0.24
  • BHRB 1.55
  • MACD
  • IOVA -0.00
  • BHRB 0.46
  • Stochastic Oscillator
  • IOVA 83.16
  • BHRB 100.00

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About BHRB Burke & Herbert Financial Services Corp.

Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.

Share on Social Networks: